10-K: Syra Health Reports Reduced Loss Amid Revenue Dip, Going Concern Warning

Syra Health Corp. reported a significantly reduced net loss for 2025, despite a 9% revenue decrease, while facing a going concern warning and delisting from Nasdaq.

Summary

• Net revenues for the year ended December 31, 2025, decreased by 9% to $7,225,973 from $7,982,082 in 2024.
• The company achieved a gross profit of $2,487,762 in 2025, an increase from $1,652,963 in 2024, with gross profit margin improving to 34% from 21%.
• Net loss significantly decreased to $896,333 in 2025 from $3,759,238 in 2024.
• Operating expenses decreased by 37% to $3,392,086 in 2025, primarily due to reductions in salaries and benefits (45% decrease) and research and development (88% decrease).
• Cash and cash equivalents stood at $1,614,733 as of December 31, 2025, down from $2,395,405 in 2024.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and an accumulated deficit of $9,720,526.
• The company's Class A common stock was voluntarily delisted from the Nasdaq Capital Market on April 11, 2025, and is now listed on the OTC QB Market.
• Gregory R. Alexander was appointed Chief Executive Officer, effective January 5, 2026, following the termination of former CEO Deepika Vuppalanchi and interim leadership by Priya Prasad.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution. While the significant reduction in net loss and improved gross margin are positive, the persistent going concern warning, overall revenue decline, decreased cash position, and delisting from Nasdaq to OTC QB indicate fundamental challenges and heightened risk for investors.

Positives

• Net loss significantly improved, decreasing by $2,862,905 to $896,333 in 2025 from $3,759,238 in 2024.
• Gross profit increased by $834,799 to $2,487,762 in 2025, with the gross profit margin improving to 34% from 21% in 2024.
• Operating expenses decreased substantially by $2,025,762, or 37%, in 2025, reflecting efforts to streamline operations and reduce overhead.
• Population health revenue increased significantly by $3,254,469 in 2025, indicating growth in this service line.
• The company launched its Syrenity mental health application in the fourth quarter of 2024, expanding its digital health offerings.
• Management believes existing cash and cash from revenue will be sufficient to fund current operations for at least 12 months from the report date.

Negatives

• Total net revenues decreased by 9% to $7,225,973 in 2025 from $7,982,082 in 2024, primarily due to a significant decline in healthcare workforce revenue.
• The company continues to incur net losses, with an accumulated deficit reaching $9,720,526 as of December 31, 2025.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern.
• Cash and cash equivalents decreased to $1,614,733 in 2025 from $2,395,405 in 2024, and working capital also declined.
• The company voluntarily delisted its Class A common stock from the Nasdaq Capital Market on April 11, 2025, moving to the less regulated OTC QB Market.
• Healthcare workforce revenue decreased by $3,993,733, or 68%, in 2025, due to fewer new customer acquisitions and lower renewal value on a key FSSA contract.
• The company is highly dependent on a small number of large customers, with FSSA accounting for 35% and Humana, Inc. for 37% of 2025 revenues, posing a concentration risk.
• The United States federal government's pausing or terminating of spending programs has led to delays in new contract awards and cancellations of previous requests for proposals, negatively affecting revenue in the near term.

Risks

• Future profitability is uncertain despite generating revenues, and the company may be unable to continue operations if profitability is not achieved and maintained.
• Substantial additional funding will be required, and inability to raise capital on favorable terms could force curtailment, delay, or discontinuation of business.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern, potentially hindering future financing.
• Failure to successfully expand sales force productivity could harm sales and business growth.
• Inability to continually update and improve existing solutions or develop new ones could lead to revenue decline.
• Achieving market acceptance for new or updated solutions requires significant efforts and expenditures and is necessary for profitability.
• Business would be adversely affected if the company cannot obtain, process, or distribute required data in compliance with laws and regulations.
• Disruptions in service, damages to data, or system failures could materially impact business, results of operations, or financial condition.
• Breaches and failures of IT systems and sensitive information expose the company to potential liability and reputational harm.
• Reliance on Internet infrastructure, bandwidth providers, data center providers, and other third parties means any failure or interruption could expose the company to litigation and negatively impact customer relationships.
• Failure by customers to obtain proper permissions or provide accurate information may result in claims or limit data use, and privacy concerns could damage reputation.
• Independent content providers may fail to perform adequately or comply with laws, regulations, or contractual covenants.
• Work with government clients exposes the company to additional risks inherent in the government contracting environment, including audits, investigations, and potential sanctions.
• Liability for misdiagnoses, mistreatment, injury, or other harm to patients resulting from the use of data provided to healthcare providers could negatively impact operating results and stock price.
• Protection of intellectual property requires substantial resources, and proprietary rights may not be adequate.
• Dependence on a small number of large customers means the loss of one or more could have a material adverse effect.
• Subject to federal and state healthcare industry regulation, including conduct of operations, costs, payment for services, and payment for referrals, as well as government contracting laws.
• The common stock is a penny stock, which may make it more difficult for investors to sell due to suitability requirements.
• Trading on the OTC QB Market may have an unfavorable impact on stock price and liquidity.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell common stock, depressing its price.
• Significant state blue sky law restrictions on resale of common stock may limit the resale market.
• The market price of Class A common stock may be volatile and fluctuate substantially, resulting in losses for holders.
• Unstable market and economic conditions and adverse developments with financial institutions may have serious adverse consequences.
• The dual-class structure of common stock concentrates voting control with Class B stockholders, limiting influence over corporate matters and potentially affecting Class A stock trading price.
• Principal stockholders continue to have significant influence over the election of the board and approval of corporate actions.
• The company could be subject to securities class action litigation.
• Anti-takeover provisions in corporate documents and Delaware law could impair a takeover attempt.
• The Certificate of Incorporation designates specific forums for certain actions, potentially limiting stockholders' ability to choose a favorable judicial forum.
• Unanticipated changes in tax laws may affect future financial results.
• Use and development of artificial intelligence products may result in reputational harm and liability.

Future Outlook

The company aims to become a leader in healthcare solutions by expanding operations, opening new offices, investing in partnerships, and potentially acquiring companies. Syrenity is being prepared for global market launch with continuous advancements in its scientific foundation and AI technology. The company is also positioning itself to work on federal government healthcare projects and participate in CMS's ACCESS Model, a 10-year national initiative launching in July 2026. However, the company anticipates needing substantial additional funding to support its growth and operations beyond the next 12 months.

Management Comments

• "We strongly believe in behavioral and mental health equity and our mission is to provide solutions that help improve health care and provide access to all populations, regardless of race, ethnicity, gender, socioeconomic status, sexual orientation, or geographic location."
• "We hope to become a leader in healthcare solutions by providing customized and comprehensive end-to-end solutions for our customers in the public and private healthcare sectors and expand our operations to other metropolitan and rural areas."
• "As we continue our expansion, we anticipate that our professional pool and infrastructure will grow to support the breadth and depth of our services."
• "With our rapid growth of sales and business development teams, we intend to replicate our current projects with similar customers across the country."
• "Our flagship product, Syrenity, is a proprietary behavioral and mental health application designed to address the growing mental health crisis. We are strategically preparing for its launch in global markets while continually advancing its scientific foundation and AI technology to enhance user outcomes."
• "Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other third-party funding or a combination of these approaches."

Industry Context

StockSavvy.ai notes that Syra Health operates within several rapidly growing healthcare markets, including behavioral health (valued at $151.7 billion in 2023, CAGR 3.7%), population health management (projected to reach $103.7 billion by 2030, CAGR 19.5%), digital health (estimated at $81.17 billion in 2023, CAGR 19.5%), health education ($110 billion in 2023, CAGR 11.0%), and healthcare staffing ($36.9 billion in 2022, CAGR 6.93%). The company's focus on AI-driven solutions like Syrenity and SyraBot aligns with the increasing demand for digital health technologies and addressing the global shortage of mental health and general healthcare professionals. The transition towards value-based healthcare delivery and the rise in healthcare IT services are key drivers for the population health market, which Syra Health is actively pursuing. However, the company's heavy reliance on government contracts exposes it to risks from federal spending program changes, a common challenge for government contractors.

Comparison to Industry Standards

• The filing highlights significant market growth rates across its service lines (e.g., Population Health CAGR of 19.5% from 2022-2030, Digital Health CAGR of 19.5% from 2024-2030). However, the filing does not provide specific comparable company performance metrics (e.g., revenue per employee, specific project success rates, or market share against direct competitors like Optum, Cerner, or Epic Systems in digital health, or major staffing firms like AMN Healthcare or Cross Country Healthcare) to assess Syra Health's performance against industry leaders or benchmarks.
• While Syra Health's gross profit margin improved to 34% in 2025, a detailed comparison to the average gross margins of publicly traded healthcare IT or staffing companies would be necessary to determine if this is competitive or below industry standards. For instance, some established healthcare IT companies might achieve higher margins due to scale and proprietary software.
• The company's revenue decline in healthcare workforce services contrasts with the overall projected growth in the U.S. healthcare staffing market (CAGR of 6.93% from 2023-2030), suggesting underperformance in a key segment relative to broader industry trends, possibly due to specific contract losses or competitive pressures not fully offset by new acquisitions.
• The development of AI-driven applications like Syrenity and SyraBot positions the company in an innovative segment, but without data on user adoption, efficacy, or competitive differentiation against established digital mental health platforms (e.g., Calm, Headspace, Teladoc's BetterHelp), a direct comparison of product success is not feasible from this filing.

Management Changes

Corporate Governance

Legal Proceedings

• A wrongful termination lawsuit filed by a former employee in January 2024 was settled on January 15, 2025, with no material impact to the company.
• The company may be a party to various legal and regulatory proceedings and investigations in the ordinary course of business, including matters involving governmental agencies and entities, and potential claims under HIPAA, Anti-Kickback Statute, False Claims Act, and other federal and state laws.

Related Party Transactions

• The company leases its corporate headquarters from STVentures, LLC, an entity beneficially owned by the principal owners and management team. Rent expense was $111,990 in 2025 and $131,516 in 2024.
• The company incurred $340,757 in 2025 and $22,233 in 2024 for outsourced IT services from RAD CUBE LLC, an entity beneficially owned by the principal owners and management team.
• For recruitment and human resource services, the company paid $155,106 to NLogix IT Services Private Limited and $250,669 to SKL Demand Private Limited in 2025. In 2024, $530,843 was paid to NLogix IT Services Private Limited. These entities are beneficially owned by the principal owners and management team.
• As of December 31, 2025, the company owed $72,000 in fees payable to directors, presented within accounts payable, related parties.

Stakeholder Impact

• **Shareholders**: Face significant risk due to the 'going concern' warning, accumulated deficit, and voluntary delisting from Nasdaq to OTC QB, which may reduce liquidity and market price volatility. The dual-class stock structure also limits influence for Class A shareholders.
• **Employees**: Headcount decreased in 2025 due to strategic streamlining, impacting some employees. The company's ability to attract and retain skilled personnel is crucial for future success.
• **Customers**: Delays in government contract awards and cancellations could impact service delivery and the company's ability to meet customer needs. Dependence on a few large customers creates risk if relationships deteriorate.
• **Creditors**: The 'going concern' warning and need for additional funding indicate potential challenges in meeting future financial obligations, increasing risk for creditors.
• **Suppliers/Partners**: Related party transactions with entities owned by management could raise questions about arm's-length dealings, though no specific negative impact is detailed. The company plans to invest in partnerships for growth.

Next Steps

• Expand operations to other metropolitan and rural areas.
• Grow professional pool and infrastructure to support service breadth and depth.
• Replicate current projects with similar customers across the country.
• Open offices in multiple geographical locations to support sales and business development.
• Invest in partnerships with subject matter experts to enhance service lines.
• Potentially expand footprint by acquiring companies that offer similar service lines.
• Strategically prepare Syrenity for launch in global markets.
• Continually advance Syrenity's scientific foundation and AI technology to enhance user outcomes.
• Work on federal government healthcare and related projects from agencies like HHS, CDC, NIH, NASA, and DoD.
• Syrenity submitted for FDA approval under the TEMPO pilot program.
• Positioning to participate in CMS's ACCESS Model, a 10-year national initiative launching July 2026.

Key Dates

Recommendation

A seasoned investor would likely recommend 'sell' for Syra Health Corp. due to several critical factors. The independent auditor's 'going concern' warning, coupled with a persistent accumulated deficit and declining cash reserves, signals significant financial instability. The voluntary delisting from Nasdaq to the less liquid OTC QB market further diminishes investor confidence and market accessibility. While the company achieved a notable reduction in net loss and an improved gross profit margin, these positives are overshadowed by a 9% decline in overall revenue and substantial risks associated with its heavy reliance on government contracts, which are experiencing delays and cancellations. The company's need for substantial additional funding in the near future, without guaranteed favorable terms, adds to the uncertainty. Despite strategic initiatives and new CEO appointment, the fundamental financial health and market position present a high-risk profile that outweighs potential future upside for a risk-averse, seasoned investor.

Keywords

Healthcare Solutions, Population Health, Behavioral Health, Mental Health, Digital Health, Healthcare Workforce, Health Education, SEC Filing, 10-K, Financial Report, Going Concern, Syrenity, AI in Healthcare, Government Contracts, OTC QB, Corporate Governance